DiaMedica Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
DMAC Nasdaq 2836 www.diamedica.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for DiaMedica Therapeutics Inc.

Insider Stock Buying Reaches US$9.00m On DiaMedica Therapeutics - Mar 17th, 2025 11:44 am
DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025 - Mar 11th, 2025 12:23 pm
DiaMedica Therapeutics Appoints Daniel J. O’Connor to the Board of Directors - Feb 24th, 2025 1:30 pm
DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke - Feb 20th, 2025 1:15 pm
DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Feb 10th, 2025 9:15 pm
Individual investors are DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) biggest owners and were hit after market cap dropped US$26m - Dec 19th, 2024 11:34 am
DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia - Dec 3rd, 2024 1:25 pm
We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate - Nov 16th, 2024 12:51 pm
Q3 2024 DiaMedica Therapeutics Inc Earnings Call - Nov 15th, 2024 7:06 am
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results - Nov 13th, 2024 9:20 pm
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia - Nov 13th, 2024 9:05 pm
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference - Nov 12th, 2024 1:23 pm
DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024 - Nov 6th, 2024 1:32 pm
Best Momentum Stocks to Buy for October 14th - Oct 14th, 2024 2:00 pm
DiaMedica gets SAHPRA approval for Phase II preeclampsia treatment trial - Oct 10th, 2024 9:28 am
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia - Oct 9th, 2024 12:27 pm
DiaMedica Therapeutics Insiders Placed Bullish Bets Worth US$9.05m - Oct 8th, 2024 10:25 am
DiaMedica Therapeutics Upcoming Conference Participation - Sep 4th, 2024 8:15 pm
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year? - Sep 3rd, 2024 1:40 pm
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results - Aug 7th, 2024 8:15 pm